Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 4, 2025Journal of Diabetes ResearchOpen Access

Astragaloside IV Improves Diabetic Kidney Disease by Regulating NLRP3 Inflammasome

View Full Paper
Ask AI
Bookmark
Share

Authors

LZLiping ZhengZKZhao Ke-qinAZAo Zeng

Discussion

Loading...

Member takes

Overview

Review finds astragaloside IV reduces pyroptosis and inflammation in diabetic kidney disease, suggesting new treatment strategies.

Key Points

  • Astragaloside IV significantly improves symptoms of diabetic kidney disease, targeting critical inflammasome pathways.
  • The treatment delays progression, demonstrating multiple mechanisms including anti-inflammatory and antioxidative effects.
  • Analysis of natural products highlights their therapeutic potential in drug design against chronic kidney complications.
  • Effective regulation of lipid metabolism disorders may enhance therapeutic efficacy for end-stage renal disease.

Cite This Study

Zheng et al. (2025) studied this question.

synapsesocial.com/papers/6930dc81ea1aef094cca23fahttps://doi.org/10.1155/jdr/3340719
View Full Paper
Ask AI
Bookmark
Share